Inhibition of cellular DNA polymerase and/or incorporation bromovinyl)-2Ј-deoxyuridine (BVDU) and closely related of the drugs into cellular DNA may be a likely target for the analogues, were evaluated for their cytostatic activity cytostatic activity of the BVDU derivatives against the against human osteosarcoma cells transfected with the VZVtk gene-transfected tumor cells. These compounds varicella-zoster virus (VZV) thymidine kinase (tk) were approximately 40-to 80-fold more potent cytostatic (ATP:thymidine 5Ј phosphotransferase, EC 2.7.2.21) gene.
Ten pyrimidine nucleoside analogues, including (E)-5-(2-
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agents
in VZVtk gene-transfected cells than the anti-VZV (E)-5-(2-bromovinyl)-1-␤-D-arabinofuranosyluracil (BVaraU), compound 6-methoxy-9-␤-D-arabinofuranosylpurine (araM), (E)-5-(2-iodovinyl)-2Ј-deoxy-2Ј-fluoro-1-␤-D-arabinofurano-
and at least five-to 50-fold more cytostatic than ganciclovir syluracil (IVFAU) and (E)-5-(2-bromovinyl)-2Ј-deoxy-4Ј-thiin HSV-1tk gene-transfected murine mammary carcinoma ouridine (S-BVDU) were among the most potent inhibitors FM3A cells. In addition, the intrinsic resistance of BVaraU, of VZVtk gene-transfected cell proliferation. They displayed IVFAU and S-BVDU to glycosidic bond cleavage by an inhibitory activity at drug concentrations that were up to mammalian dThd phosphorylases makes them promising four orders of magnitude lower than those required to candidate compounds for the treatment of VZVtk geneinhibit the corresponding nontransfected tumor cells.
transfected tumors in vivo.
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In the past decade, traditional anticancer therapies (ie selectively sensitive to chemotherapeutic agents. These susceptibility genes, often of viral or prokaryotic origin, surgical resection, radiotherapy and chemotherapy) have not resulted in major breakthroughs on therapeutic are designated 'suicide genes', because they trigger the transfected cell to commit metabolic suicide by conimprovements. Current antineoplastic drugs are struggling with the limited ability to distinguish neoplastic verting the chemotherapeutic agent into a highly toxic metabolite that is able to kill the transfected cell. [1] [2] [3] If the cells from normal cells on the basis of proliferative functions. Also, because tumor cells, in general, use the same suicide gene can be targeted specifically to tumor cells (eg by the use of retroviral vectors only integrating in metabolic pathways as nonmalignant cycling cells, the lack of significant biochemical differences between noractively dividing cells, or by the insertion of tissue-or tumor-specific promotor/enhancer sequences), selective mal and tumor cells prevent a marked improvement of the selectivity of most chemotherapeutics. However, killing of the tumor cells may be achieved without significant toxicity to adjacent tissues. [4] [5] [6] advances in gene technology offer new possibilities for the treatment of malignancies, including the artificial creThe most intensively studied suicide gene/prodrug system is represented by the herpes simplex virus type ation of exploitable biochemical differences between neoplastic and non-neoplastic cells. Following the insertion 1 (HSV-1) thymidine kinase (tk) gene in combination with the antiherpetic drug ganciclovir (Cymevene; Gilead in tumor cells of genes encoding for specific enzymes not normally present in mammalian cells, metabolic pathSciences, CA, USA). 2, 3, 7, 8 This acyclic guanosine derivative needs to be monophosphorylated by the viral tk, and ways can be altered in order to make these tumor cells is subsequently metabolized by cellular enzymes to the triphosphate form in order to exert its deleterious effect on DNA polymerization, resulting in cell killing. The first The arabinosylnucleosides araT and araU were devoid of pronounced inhibition of the thymidine kinase activity at activation by VZVtk gene-transfected cells of the nontoxic prodrug 6-methoxy-9-␤-d-arabinofuranosylpurine (araM) concentrations р100 m ( Table 2 ). The pyrimidine nucleoside analogues were then evaluto the DNA polymerase inhibitor 9-␤-d-arabinofuranosyladenine-5Ј-triphosphate (araATP). Our choice of VZVtk ated for their inhibitory effects on the proliferation of human osteosarcoma cells deficient in cytosol tk (Osttk − ) as a prodrug-activating enzyme originated from the findings that several pyrimidine nucleoside analogues and the two VZVtk gene-transfected osteosarcoma cell lines derived from Osttk − . As shown in Table 3 , none of (eg BVDU, (E)-5-(2-iodovinyl)-2Ј-deoxyuridine (IVDU), and Figure 2 . VZVtk gene-transfected cells were centrations that proved Ͼ5000-to Ͼ10 000-fold lower than those required to inhibit the parental Osttk − cells selected, based upon the inability of tk − cells to grow in HAT medium. The transfected cell lines were selected (Table 3) . Their cytostatic activity against the VZVtk genetransfected tumor cells was even five-to 20-fold more under independent experimental conditions and designated Osttk − /VZVtk + -a and Osttk − /VZVtk + -b. The growth pronounced than that of the prototype compounds BVDU and IVDU. In sharp contrast with araU, the arabirate of the VZVtk gene-transfected Osttk − cells was only slightly decreased when compared with the growth rate nosyl nucleosides araT and BVaraU were 500-fold (araT) and 1500-fold (BVaraU) more potent in their cytostatic of untransfected Osttk − cells (data not shown). Successful VZVtk gene transfection was not only indicated by the activity against Osttk − /VZVtk + -a and Osttk − /VZVtk + -b cells than against the nontransfected Osttk − cells (Table 3) . dThd phosphorylating capacity of Osttk − /VZVtk + -a and Osttk − /VZVtk + -b cell extracts (ie 66 and 31 pmol methylIn our studies, 6-methoxy-9-␤-d-arabinofuranosylpurine (araM, provided by B Kozalsky (Glaxo-Wellcome, NC, 3 H-dThd converted per milligram of protein per minute) but also by the sensitivity of Osttk − /VZVtk + -a and USA)), previously described as a selective chemothera- 21 After a 2-h incubation period, residual virus was removed and the infected cells were further incubated (in duplicate) with MEM supplemented with 2% inactivated fetal calf serum (Integro, Zaandam, The Netherlands), 2 mm l-glutamine (Gibco, Paisley, UK) and 0.045% (w/v) NaHCO 3 (Gibco) and containing serial dilutions of the test compounds. After 5 days of incubation at 37°C in a humidified CO2-controlled atmosphere, virus plaque formation was determined. IC50, 50% inhibitory concentration, or concentration required to reduce virus plaque formation by 50%; ND, not determined.
Figure 1 Chemical structures of BVDU and related compounds. BVDU ((E)-5-(2-bromovinyl)-2Ј-deoxyuridine), IVDU ((E)-5-(2-iodovinyl)-2Ј-deoxyuridine) and BVDC ((E)-5-(2-bromovinyl)-2Ј-deoxycytidine) were synthesized by P Herdewijn and A Van Aerschot at the Rega Institute for Medical Research (Katholieke Universiteit Leuven, Belgium). BVaraU ((E)-5-(2-bromovinyl)-1-␤-d-arabinofuranosyluracil) was provided by H Machida (Yamasa Shoyu Co, Choshi, Japan). S-BVDU ((E)-5-(2-bromovinyl)-2Ј-deoxy-4Ј-thiouridine) and CVDU ((E)-5-(2-chlorovinyl)-2Ј-deoxyuridine) were synthesized by I Basrah and RT Walker (University of Birmingham, UK). IVFRU ((E)-5-(2-iodovinyl)-2Ј-deoxy-2Ј-fluoro-1-␤-d-ribofuranosyluracil) and IVFAU ((E)-5-(2-iodovinyl)-2Ј-deoxy-2Ј-fluoro-1-␤-d-arabinofuranosyluracil) were synthesized by K Morin, E Knaus and L Wiebe (University of Alberta, Canada), whereas araU (1-␤-d-arabinofuranosyluracil) and araT (1-␤-d-arabinofuranosylthymine) were from Sigma Chemical Co. (St Louis, MO, USA).
peutic drug for the tk gene-mediated elimination of hepa-(TS) is the principal target for the cytostatic activity of BVDU and related compounds against HSVtk gene-transtocellular carcinoma cells by Huber et al 19 was used as a positive control. It displayed an IC 50 value in the lower fected murine mammary carcinoma FM3A cells. 15, 17 Thymidylate synthase, which catalyzes the reductive methylmicromolar range for VZVtk gene-transfected osteosarcoma cells, and thus was 40 to 80 times less potent than ation of dUMP to dTMP, is a crucial enzyme in the de novo pathway of dTMP synthesis in the cell. It is con-S-BVDU and IVFAU (data not shown).
We have previously shown that thymidylate synthase sidered as the principal target enzyme for the anticancer H-dThd to a 12-fold higher extent than the noninhibitory concentrations that fell within the 0.65-1.5 m range, and thus at more than 65-to 150-fold lower contransfected Osttk − cells after a 24-h incubation period. Moreover, when the cell lines were incubated for 24 h in centrations than those required to inhibit tritium release in Osttk − cells. Surprisingly, IVFRU and S-BVDU were the presence of 2Ј-3 H-BVDU, a 17-fold higher incorporation of drug-derived radioactivity was observed in markedly less inhibitory to tritium release from 5- There are major differences in the cytostatic potential of the pyrimidine nucleoside analogues against VZVtk of control at 100 m (data not shown). Except for IVFAU, the cellular DNA polymerase(s). Alternatively, BVaraU of thymidylate synthase and cell proliferation for BVDU, and assayed for dThd kinase activity as described before. the incorporation of the drug into cellular DNA and/or inhibition of DNA polymerase as the molecular basis of the cytostatic activity of BVDU and related compounds against VZVtk gene-transfected Osttk − cells. An interesting feature of the BVDU and IVDU derivaand HSVtk gene-transfected tumor cells. In contrast with BVDU, the arabinosyl nucleoside BVaraU has previously tives that are most inhibitory against Osttk − /VZVtk + cell proliferation (ie BVaraU, S-BVDU and IVFAU) is their been found not to be inhibitory against the HSVtk genetransfected murine mammary carcinoma FM3Atk − /HSVintrinsic property to resist phosphorolytic cleavage by mammalian dThd phosphorylase. Indeed, BVaraU, S1tk + and FM3Atk − /HSV-2tk + cells. 7 These findings were interpreted to mean that TS is not a target for the cyto-BVDU and IVFAU are known to have poor, if any, susceptibility to glycosidic hydrolysis compared with BVDU static action of the drug. This conclusion has been corroborated by previous reports that arabinofuranosylnucleoand IVDU. 24, 25 This property may give the compounds described in this study a therapeutic edge over the phostides usually have poor affinity for TS. 23 9.3 ± 4.9 9.8 ± 2.7 IVFRU Ͼ100 у100 у100 IVFAU у100 3.9 ± 1.9 2.7 ± 0.69 BVaraU Ͼ100 у100 у100 araT Ͼ100 у100 у100 araU Ͼ100 у100 у100 3 H-dCyd (1 Ci) (specific radioactivity, 18.1 or 24 Ci/mmol) (Radiochemical Centre, Amersham, UK) was added to each well and the cells were further incubated at 37°C. One hour later, 500 l of a cold suspension (0.1 g/ml) of carbon black (UCB, Leuven, Belgium) in 5% TCA was added and the resulting mixture was centrifuged at 1100 g for 10 min. Supernatants were analyzed for radioactivity in a toluene-based scintillant. IC50, 50% inhibitory concentration, or the drug concentration required to inhibit the release of tritium by 50%; mean value (±s.d.) for three to five independent experiments. the growth of VZVtk gene-transfected tumor cells (ie IC 50 :
than the cytostatic activity of ganciclovir against HSV-1tk gene-transfected tumor cells. In addition, the principal 0.02-0.2 m) ( Table 3 ) than ganciclovir to HSV-1tk genetransfected tumor cells (ie IC 50 : 1 m).
18,26 These obserintracellular target of the most potent compounds did not prove to be thymidylate synthase, and thus, clearly difvations suggest that VZVtk gene transfection may be a useful approach for the combined fers from the target of these pyrimidine nucleoside analogues in HSVtk gene-transfected cells. gene/chemotherapy of tumors.
In conclusion, we reported on the feasibility of using the VZVtk gene as a suicide gene for combined 
